Total votes: 2

Genera Biosystems Limited is a company that develops and commercialises multiplexed molecular diagnostic tests, based upon its proprietary AmpaSandTM bead-based technology. Genera's products compete in the global market for molecular diagnostic tests and are used by commercial pathology providers. AmpaSand beads are a platform for the kind of medium density multiplexed tests (5-150 analytes) of most use to pathology labs. AmpaSand bead-based tests are marketed as high throughput, simple to use, and leverage existing laboratory infrastructure and expertise.

Genera's first product on sale is PapTypeTM, amolecular diagnostic test for the simultaneous detection and genotyping of the 14 types human papillomavirus (HPV). The company has a number of other products in its development pipeline. Genera manufactures its products at a custom-built facility in Melbourne, Australia.

Genera is also in the development of stage of a next-generation, ultra-sensitive, real-time detection system, which will have utility in a wide range of medical and non-medical applications.

The compnay claims to have one teir 1 industry partner.

Finances:

On the 28th of February 2011 the company lodged a Prospectus with ASIC to raise $2.95M in a Rights Issue.

As of the 31st of December the company had approx. $1.3M in cash.